CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER

MLA

Pilar Lianes, et al. “Cn2 Economic Evaluation of New Poly-Chemotherapy Regimens as Alternatives to Cisplatin Plus Paclitaxel in Advanced Non-Small Cell Lung Cancer.” Value in Health, no. 6, pp. 443–44. EBSCOhost, https://doi.org/10.1016/S1098-3015(10)61194-1. Accessed 16 Dec. 2024.

APA

Pilar Lianes, E.F. Smit, J van Meerbeeck, G. Giaccone, & Niels Neymark. (n.d.). Cn2 Economic Evaluation of New Poly-Chemotherapy Regimens as Alternatives to Cisplatin Plus Paclitaxel in Advanced Non-Small Cell Lung Cancer. Value in Health, 6, 443–444. https://doi.org/10.1016/S1098-3015(10)61194-1

Chicago

Pilar Lianes, E.F. Smit, J van Meerbeeck, G. Giaccone, and Niels Neymark. 2024. “Cn2 Economic Evaluation of New Poly-Chemotherapy Regimens as Alternatives to Cisplatin Plus Paclitaxel in Advanced Non-Small Cell Lung Cancer.” Value in Health, no. 6: 443–44. Accessed December 16. doi:10.1016/S1098-3015(10)61194-1.